1 February 2012 - Swiss pharmaceutical group Novartis (VTX:NOVN) said on Wednesday that the US Food and Drug Administration (FDA) had approved a change in the label of the company's Gleevec (imatinib mesylate) tablets to recommend 36 months of treatment after surgery for adult patients with KIT...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up